Bacteriophage Virus-Like Particles: Platforms for Vaccine Design.
Bacteriophage Virus-Like Particles: Platforms for Vaccine Design.
复制标题
噬菌体病毒样颗粒：疫苗设计平台。
DOI：
10.1007/978-1-0716-3549-0_24
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Tumban,Ebenezer
中科院分区：
文献类型：
--
作者：
Tumban,Ebenezer
来源于噬菌体的病毒样颗粒（Virus-like particles，VLP）在生物医学科学中有许多应用，特别是在针对病毒和细菌感染的候选疫苗的开发中。与真核表达系统相比，噬菌体VLP可以在细菌中廉价且大量地制造。除此之外，噬菌体VLP是疫苗设计的极好平台，原因如下：人类没有针对噬菌体VLP的预先存在的抗体。因此，预期在噬菌体VLP平台上展示的抗原是高度免疫原性的。因此，衍生自MS 2、PP 7、Qβ、AP 205、P22噬菌体等的VLP已用于开发针对人感染性和非感染性因子的候选疫苗。这篇小型综述总结了一些已经开发的候选噬菌体VLP肽疫苗的数据。本文还重点介绍了一些用于开发候选噬菌体VLP肽疫苗的策略。
Virus-like particles (VLPs) derived from bacteriophages have many applications in biomedical sciences, especially in the development of candidate vaccines against viral and bacterial infections. Bacteriophage VLPs can be manufactured cheaply and in large quantities in bacteria compared to eukaryotic expression systems. In addition to this, bacteriophage VLPs are excellent platforms for vaccine design for the following reason: Humans do not have preexisting antibodies against bacteriophage VLPs. Thus, antigens displayed on bacteriophage VLP platforms are expected to be highly immunogenic. As such, VLPs derived from MS2, PP7, Qβ, AP205, P22 bacteriophages, etc. have been used to develop candidate vaccines against human infectious and noninfectious agents. This mini-review summarizes data from some of the candidate bacteriophage-based VLP peptide vaccines that have been developed. The review also highlights some strategies used to develop the candidate bacteriophage-based VLP peptide vaccines.